Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma

This study investigated cetuximab added to definitive concurrent chemoradiation for esophageal squamous cell carcinoma (ESCC). Previously untreated patients with stage II–IVa ESCC received cetuximab (400 mg/m(2) per week in week 1, then 250 mg/m(2) per week during weeks 2–8), paclitaxel (45 mg/m(2)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Chen, Yongshun, Wu, Xiaoyuan, Bu, Shanshan, He, Chunyu, Wang, Wen, Liu, Jinsong, Guo, Wei, Tan, Bo, Wang, Yanxia, Wang, Jianhua
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2012
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5439109/
https://ncbi.nlm.nih.gov/pubmed/22845557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02393.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados